Amgen Inc. (NASDAQ:AMGN) Receives $354.60 Average Price Target from Brokerages

Shares of Amgen Inc. (NASDAQ:AMGN) have been given a consensus rating of “Hold” by the thirty ratings firms that are currently covering the stock, Marketbeat.com reports. Two research analysts have rated the stock with a sell recommendation, thirteen have given a hold recommendation, fourteen have issued a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month price target among brokerages that have issued a report on the stock in the last year is $355.00.

AMGN has been the topic of several recent analyst reports. Daiwa Securities Group upped their price objective on shares of Amgen from $370.00 to $410.00 and gave the company an “outperform” rating in a report on Tuesday, February 10th. Sanford C. Bernstein downgraded shares of Amgen from an “outperform” rating to a “market perform” rating and set a $335.00 price objective on the stock. in a report on Tuesday, January 20th. The Goldman Sachs Group upped their price objective on shares of Amgen from $403.00 to $415.00 and gave the company a “buy” rating in a report on Wednesday, February 4th. Rothschild & Co Redburn upped their price objective on shares of Amgen from $180.00 to $200.00 and gave the company a “sell” rating in a report on Wednesday, February 18th. Finally, Morgan Stanley upped their price objective on shares of Amgen from $304.00 to $309.00 and gave the company an “equal weight” rating in a report on Wednesday, February 4th.

Key Amgen News

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Phase‑3 win — Amgen’s subcutaneous TEPEZZA met primary and key secondary endpoints (77% proptosis response, clinically meaningful ≥3 mm reduction), matching IV efficacy and offering faster dosing that could broaden access. AMGN’s Subcutaneous Tepezza Scores Phase III Win in Thyroid Eye Disease
• Positive Sentiment: Analyst support — RBC Capital raised its price target to $370 and kept an Outperform rating, signaling institutional confidence in Amgen’s commercial prospects for TEPEZZA. RBC raises AMGN price target to $370
• Neutral Sentiment: Market interest rising — Retail and institutional attention to AMGN has increased (search/coverage pieces from Zacks/Yahoo), which can amplify intraday moves but is not a directional catalyst by itself. Investors Heavily Search Amgen Inc. (AMGN)
• Neutral Sentiment: Competitive read — Stifel notes Amgen’s topline compares favorably to Viridian’s data on absolute and placebo‑adjusted response, but highlights that Viridian’s subcutaneous injection profile could still differentiate in the market—keeping competitive uncertainty alive. Stifel sees path towards differentiation for Viridian after Amgen data
• Negative Sentiment: Stock weakness despite data — Multiple reports note Amgen shares fell intraday even after the positive TEPEZZA readout; investors may be taking profits, weighing execution/commercialization risk, or reacting to remaining competitive questions. Amgen Posts 77% Response In Thyroid Eye Disease Study

Institutional Investors Weigh In On Amgen

Large investors have recently bought and sold shares of the company. Anfield Capital Management LLC boosted its position in Amgen by 1,000.0% in the fourth quarter. Anfield Capital Management LLC now owns 77 shares of the medical research company’s stock valued at $25,000 after buying an additional 70 shares during the last quarter. Dogwood Wealth Management LLC boosted its position in Amgen by 275.0% in the 4th quarter. Dogwood Wealth Management LLC now owns 75 shares of the medical research company’s stock worth $25,000 after purchasing an additional 55 shares in the last quarter. Board of the Pension Protection Fund purchased a new stake in Amgen in the 4th quarter worth approximately $26,000. Howard Hughes Medical Institute purchased a new stake in Amgen in the 2nd quarter worth approximately $32,000. Finally, Manning & Napier Advisors LLC boosted its position in Amgen by 49.2% in the 4th quarter. Manning & Napier Advisors LLC now owns 97 shares of the medical research company’s stock worth $32,000 after purchasing an additional 32 shares in the last quarter. Hedge funds and other institutional investors own 76.50% of the company’s stock.

Amgen Stock Performance

AMGN opened at $340.00 on Wednesday. Amgen has a 52-week low of $261.43 and a 52-week high of $391.29. The company has a quick ratio of 0.90, a current ratio of 1.14 and a debt-to-equity ratio of 5.78. The company has a market cap of $183.28 billion, a P/E ratio of 23.89, a price-to-earnings-growth ratio of 3.45 and a beta of 0.47. The firm’s 50-day moving average price is $363.28 and its 200-day moving average price is $334.04.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings data on Tuesday, February 3rd. The medical research company reported $5.29 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.76 by $0.53. Amgen had a net margin of 20.98% and a return on equity of 148.37%. The firm had revenue of $9.87 billion for the quarter, compared to the consensus estimate of $9.46 billion. During the same quarter in the prior year, the company posted $5.31 earnings per share. The company’s revenue for the quarter was up 8.6% compared to the same quarter last year. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. As a group, equities analysts anticipate that Amgen will post 20.62 EPS for the current fiscal year.

Amgen Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, June 5th. Investors of record on Friday, May 15th will be given a $2.52 dividend. The ex-dividend date is Friday, May 15th. This represents a $10.08 dividend on an annualized basis and a yield of 3.0%. Amgen’s dividend payout ratio is currently 70.84%.

About Amgen

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.